Back to results
US 11,111,313 B2Granted
Anti-PCSK9 antibodies
AssigneeWuxi Biologics Ireland Limited
InventorsJieying Liu, Jing Li
Life of this patent
Estimating the term…
Abstract
The present disclosure provides monoclonal antibodies against Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9), which can block the binding of PCSK9 to low-density lipoprotein (LDL) receptor, and therefore lower the level low-density lipoprotein cholesterol (LDL-C). The antibodies of disclosure provide very potent agents for the treatment of multiple Cardiovascular diseases (CVDs).
Claims12
An isolated antibody or an antigen binding fragment thereof, comprising:
- a heavy chain variable region comprising an HCDR1 comprising SEQ ID NO:
- 13, an HCDR2 comprising SEQ ID NO:
- 15, and an HCDR3 comprising SEQ ID NO:
- 17;
- and a light chain variable region comprising an LCDR1 comprising SEQ ID NO:
- 19, an LCDR2 comprising SEQ ID NO:
- 21, and an LCDR3 comprising SEQ ID NO:
- 23, wherein the isolated antibody or an antigen binding fragment thereof specifically binds to Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9).
5 more elements
Dependencies are inferred from the claim text.